The bile acid TUDCA and neurodegenerative disorders: An overview.

  title={The bile acid TUDCA and neurodegenerative disorders: An overview.},
  author={Lucas Zangerolamo and Jean Franciesco Vettorazzi and Lucas Rodolfo de Oliveira Rosa and Everardo Magalh{\~a}es Carneiro and Helena C L Barbosa},
  journal={Life sciences},

Energy homeostasis deregulation is attenuated by TUDCA treatment in streptozotocin-induced Alzheimer’s disease mice model

It is demonstrated that TUDCA treatment restores energy metabolism in Stz mice, a phenomenon that is associated with reduced food intake, increased EE and improved hypothalamic leptin signaling.

Effects of the investigational drug sodium phenylbutyrate-TUDCA (AMX0035) on the transcriptional and metabolic landscape of sporadic ALS fibroblasts

It is shown that Combo has a greater and distinct impact compared to the individual compounds and provides clues to drug targets and mechanisms of actions, which may underlie the benefits of this investigational drug combination.

Role of Gut Microbiota in Bile-Acid Metabolism

The importance of gut microbiota-bile acid-receptor signals when considering nutritional approaches to promote healthy longevity is emphasized, and the development of metagenomic analysis for gut microbiota and systematic bile-acid measurement using LC–MS/MS is triggered.

Tauroursodeoxycholic Acid Attenuates Diet-Induced and Age-Related Peripheral Endoplasmic Reticulum Stress and Cerebral Amyloid Pathology in a Mouse Model of Alzheimer’s Disease

Peripheral administration of TUDCA suppressed ER stress in the peripheral tissues and ameliorated the HFD-induced obesity and insulin resistance, and markedly reduced amyloid accumulation.

Tauroursodeoxycholic acid (TUDCA) improves intestinal barrier function associated with TGR5-MLCK pathway and the alteration of serum metabolites and gut bacteria in weaned piglets

Findings showed that TUDCA improved intestinal barrier function associated with TGR5-MLCK pathway and the alteration of serum metabolites and gut bacteria in weaned piglets, suggesting the potential application of TudCA in improving gut health in piglet production.

Bile Acids as Key Modulators of the Brain-Gut-Microbiota Axis in Alzheimer’s Disease

  • A. Mulak
  • Biology
    Journal of Alzheimer's disease : JAD
  • 2021
Experimental and clinical data confirm that disturbances in BA signaling are present in the course of AD and new therapeutic targets have been explored including gut microbiota modulation by probiotics and dietary interventions, ursodeoxycholic acid supplementation, and use of BA receptor agonists.

Effects of PB‐TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts

The goal was to obtain an unbiased landscape of the molecular effects of AMX0035 in ALS patient‐derived cells.



The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases

Tauroursodeoxycholic acid (TUDCA) is the taurine conjugate of ursodeoxycholic acid (UDCA), a US Food and Drug Administration—approved hydrophilic bile acid for the treatment of certain cholestatic

Tauroursodeoxycholate—Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives

TUDCA has been demonstrated to display potential therapeutic benefits in various models of many diseases such as diabetes, obesity, and neurodegenerative diseases, mostly due to its cytoprotective effect.

Effects of bile acids on neurological function and disease

  • Matthew McMillinS. DeMorrow
  • Biology
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2016
This review summarizes recent findings on the influences that bile acids can exert in normal neurological function and their contribution to diseases of the nervous system, with the intent of highlighting the role of these metabolites as potential players in neurological disorders.

Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications

Clinical and experimental work that may help to clarify possible mechanisms of action of UDCA in cholestasis and provide a clearer rationale for the administration ofUDCA in special cholESTatic disorders are summarized.

TUDCA: An Agonist of the Bile Acid Receptor GPBAR1/TGR5 With Anti‐Inflammatory Effects in Microglial Cells

The bile acid receptor GPBAR1/TGR5 could be a new therapeutic target for pathologies coursing with neuroinflammation and microglia activation, such as traumatic brain injuries, stroke, or neurodegenerative diseases.

Tauroursodeoxycholic Acid Partially Prevents Apoptosis Induced by 3‐Nitropropionic Acid

TUDCA inhibits 3‐NP‐induced apoptosis via direct inhibition of mitochondrial depolarization and outer membrane disruption, together with modulation of Bax translocation from cytosol to mitochondria, and cell death by 3‐ NP apparently occurs through pathways that are independent of the MPT.

Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1).

In vivo and in vitro pharmacological evaluation demonstrated that administration of compound 16 selectively increases the expression of pro-glucagon 1, a GP-BAR1 target, in the small intestine, while it had no effect on FXR target genes in the liver.

Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats

  • C. RodriguesS. Solá C. Steer
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2003
Reduction of brain injury underlies the wide-range neuroprotective effects of TUDCA after ICH and may provide a potentially useful treatment in patients with hemorrhagic stroke and perhaps other acute brain injuries associated with cell death by apoptosis.